<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074656</url>
  </required_header>
  <id_info>
    <org_study_id>DIA2016-1</org_study_id>
    <nct_id>NCT03074656</nct_id>
  </id_info>
  <brief_title>The Norwegian Drug Monitoring Study</brief_title>
  <acronym>NOR-DRUM</acronym>
  <official_title>A NORwegian Multicentre Randomised Controlled Trial Assessing the Effectiveness of Tailoring Infliximab Treatment by Therapeutic DRUg Monitoring - The NOR-DRUM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diakonhjemmet Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infliximab and other TNF-inhibitors have revolutionised the treatment of several
      immunological inflammatory diseases. Still, more than half of the patients either do not
      respond sufficiently to infliximab therapy or loose efficacy over time. The large individual
      variation in the serum drug concentrations on standard doses and the development of anti-drug
      antibodies are thought to be main reasons for these treatment failures. An individualised
      treatment strategy based on systematic assessments of serum drug concentrations, therapeutic
      drug monitoring, has been proposed as a clinical tool to optimise efficacy of infliximab
      treatment. Therapeutic drug monitoring seems reasonable both from a clinical and an
      economical point of view, but the effectiveness of this treatment strategy still remain to be
      shown. The NOR-DRUM study is planned as a national, randomised controlled multicentre trial
      in two parts aiming to assess the effectiveness of therapeutic drug monitoring in order to
      achieve remission in patients with immunological inflammatory diseases starting infliximab
      treatment (part A) and in order to maintain disease control in patients on maintenance
      infliximab treatment (part B). The results of the NOR-DRUM study will hopefully contribute to
      an implementation of a personalised medicine approach to treatment with infliximab and other
      biological drugs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in remission defined by disease specific composite scores</measure>
    <time_frame>30 weeks</time_frame>
    <description>Study part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained disease control throughout the study period without disease worsening defined by disease specific composite scores</measure>
    <time_frame>52 weeks</time_frame>
    <description>Study part B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to sustained remission</measure>
    <time_frame>30 weeks</time_frame>
    <description>Part A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and physician's global assessment of disease activity</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ESR</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-drug antibodies</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for drug discontinuation</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of drug discontinuation</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B (Incremental QALYs of the intervention arm and active comparator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B (Cost-effectiveness ratios (ICERs) of the intervention arm and active comparator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health utility (EQ-5D)</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>Part A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events frequency)</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by composite disease activity scores</measure>
    <time_frame>30 weeks (A) and 52 weeks (B)</time_frame>
    <description>A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease worsening</measure>
    <time_frame>52 weeks</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Spondyloarthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Psoriasis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Therapeutic drug monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of infliximab according to a treatment strategy based on therapeutic drug monitoring and assessments of anti-drug antibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of infliximab according to standard clinical care, without knowledge of drug levels or status of anti-drug antibodies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic drug monitoring</intervention_name>
    <description>Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies</description>
    <arm_group_label>Therapeutic drug monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        NOR-DRUM A

          1. A clinical diagnosis of one of the following; rheumatoid arthritis, spondyloarthritis
             (including ankylosing spondylitis), psoriatic arthritis*, ulcerative colitis, Crohn's
             disease or chronic plaque psoriasis

          2. Male or non-pregnant female

          3. â‰¥18 and &lt; 75 years of age at screening

          4. A clinical indication to start INX

          5. Subject not in remission according to diagnosis-specific disease activity scores

          6. Subject capable of understanding and signing an informed consent form

               -  Patients with psoriatic arthritis with predominantly axial manifestations should
                  be included and assessed as spondyloarthritis

        NOR-DRUM B

          1. A clinical diagnosis of one of the following; rheumatoid arthritis, spondyloarthritis
             (including ankylosing spondylitis), psoriatic arthritis*, ulcerative colitis, Crohn's
             disease or chronic plaque psoriasis

          2. Male or non-pregnant female

          3. â‰¥18 and &lt; 75 years of age at screening

          4. On maintenance therapy with infliximab for a minimum of 30 weeks and a maximum of 3
             years

          5. A clinical indication for further infliximab treatment

          6. Subject capable of understanding and signing an informed consent form

               -  Patients with psoriatic arthritis and predominantly axial manifestations should
                  be included and assessed as spondyloarthritis

        Exclusion Criteria:

        NOR-DRUM A

          1. Major co-morbidities, such as previous malignancies within the last 5 years, severe
             diabetes mellitus, severe infections (including HIV), uncontrollable hypertension,
             severe cardiovascular disease (NYHA class 3 or 4), severe respiratory diseases,
             demyelinating disease, significant chronic widespread pain syndrome, laboratory
             abnormalities or significant renal or hepatic disease and/or other diseases or
             conditions where treatment with infliximab is either found contra-indicated by the
             clinician or which make adherence to the protocol difficult

          2. A positive screening for TB and hepatitis

          3. Inadequate birth control, pregnancy or subject considering becoming pregnant during
             the study period

          4. Psychiatric or mental disorders, alcohol abuse or other substance abuse, language
             barriers or other factors which makes adherence to the study protocol difficult

          5. Prior use of infliximab within the last 6 months

        NOR-DRUM B

          1. Major co-morbidities, such as previous malignancies within the last 5 years, severe
             diabetes mellitus, severe infections, uncontrollable hypertension, severe
             cardiovascular disease (NYHA class 3 or 4), severe respiratory diseases, demyelinating
             disease, significant chronic widespread pain syndrome, laboratory abnormalities or
             significant renal or hepatic disease and/or other diseases or conditions where
             treatment with infliximab is either found contra-indicated by the clinician or which
             make adherence to the protocol difficult

          2. Inadequate birth control, pregnancy or subject considering becoming pregnant during
             the study period

          3. Psychiatric or mental disorders, alcohol abuse or other substance abuse, language
             barriers or other factors which makes adherence to the study protocol difficult
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Espen A Haavardsholm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diakonhjemmet Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tore K Kvien, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Diakonhjemmet Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silje W Syversen, MD, PhD</last_name>
    <phone>+47 22451500</phone>
    <email>s.w.syversen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Espen A Haavardsholm, MD, PhD</last_name>
    <phone>+47 22451500</phone>
    <email>e.a.haavardsholm@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Oslo</city>
        <state>LÃ¸renskog</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin KÃ¥sin JÃ¸rgensen, MD, PhD</last_name>
      <email>krikjo@online.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SÃ¸rlandet Sykehus, Arendal</name>
      <address>
        <city>Arendal</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geir Noraberg, MD</last_name>
      <email>Geir.Noraberg@sshf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland, HELSE BERGEN HF,</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>KÃ¥re Steinar Tveit, MD</last_name>
      <email>Kaare.steinar.tveit@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BodÃ¸, NORDLANDSSYKEHUSET</name>
      <address>
        <city>BodÃ¸</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rune NjÃ¥lla, MD</last_name>
      <email>rune.johan.njalla@nordlandssykehuset.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Drammen, VESTRE VIKEN HF</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yngvill Bragenes, MD</last_name>
      <email>Yngvill.Hovde.Bragnes@vestreviken.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elverum, SYKEHUSET INNLANDET HF</name>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Magnus YstrÃ¸m, MD</last_name>
      <email>carl.magnus.ystrom@sykehuset-innlandet.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helse FÃ¸rde Hf</name>
      <address>
        <city>FÃ¸rde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Mielnik, MD</last_name>
      <email>pawel.franciszek.mielnik@helse-forde.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamar, SYKEHUSET INNLANDET HF</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roald Torp, MD</last_name>
      <email>Roald.A.Torp@sykehuset-innlandet.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HAUGESUND SANITETSFORENING revmatismesykehus</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svanaug Skorpe, MD</last_name>
      <email>svanaug.skorpe@hsr.as</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haugesund Sjukehus</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Blomgren, MD</last_name>
      <email>ingrid.marianne.blomgren@helse-fonna.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SÃ˜RLANDET SYKEHUS HF Kristiansand</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Michelsen, MD</last_name>
      <email>brigitte_michelsen@yahoo.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>REVMATISMESYKEHUSET AS, Lillehammer</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eldrid Strand</last_name>
      <email>Eldri.Kveine.Strand@revmatismesykehuset.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset Ã˜stfold Moss</name>
      <address>
        <city>Moss</city>
        <zip>1535</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Haugen, MD, PhD</last_name>
      <email>Anne.Julsrud.Haugen@so-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ã˜ystein Sandanger, MD, PhD</last_name>
      <email>oystein.sandanger@rr-research.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonhjemmet Sykehus</name>
      <address>
        <city>Oslo</city>
        <zip>0687</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silje W Syversen, MD, PhD</last_name>
      <phone>+4792040315</phone>
      <email>s.w.syversen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Silje W Syversen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Betanien Hospital</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla Zettel, MD</last_name>
      <email>camilla.zettel@betanienhospital.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger Universitetssjukehus</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Karlsen, MD</last_name>
      <email>lars.normann.karlsen@sus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TromsÃ¸, UNIVERSITETSSYKEHUSET NORD-NORGE HF</name>
      <address>
        <city>TromsÃ¸</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trude Brun, MD</last_name>
      <email>trude.jannecke.bruun@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Skjetne, MD</last_name>
      <email>kristine.skjetne@stolav.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset Vestfold, TÃ¸nsberg</name>
      <address>
        <city>TÃ¸nsberg</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrine Seeberg, MD</last_name>
      <email>UXSEEK@siv.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ã…lesund, HELSE MÃ˜RE OG ROMSDAL HF</name>
      <address>
        <city>Ã…lesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud Kristine Aga LjosÃ¥, MD</last_name>
      <email>maud-kristine.aga.ljosa@helse-mr.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diakonhjemmet Hospital</investigator_affiliation>
    <investigator_full_name>Espen A. Haavardsholm, MD PhD</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>infliximab</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <keyword>anti drug antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

